FIbromyalgia anD GenetIcs Subgroups (FIDGIS)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Fibromyalgia
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: Non-RandomizedIntervention Model: Single Group AssignmentIntervention Model Description: Exploratory case control pathophysiology study of psychophysical (central sensitization assessment) and genetic (candidate gene panel) characteristics.Masking: None (Open Label)Primary Purpose: Basic Science
Participation Requirements
- Age
- Between 18 years and 65 years
- Gender
- Both males and females
Description
This is an exploratory case control pathophysiology study of psychophysical (central sensitization assessment) and genetic (candidate gene panel) characteristics. The main objectives of this study are : Primary: Evaluate the central nociception sensitization characteristics and genetic determinants ...
This is an exploratory case control pathophysiology study of psychophysical (central sensitization assessment) and genetic (candidate gene panel) characteristics. The main objectives of this study are : Primary: Evaluate the central nociception sensitization characteristics and genetic determinants in fibromyalgic syndrome, comparing a group of patients to matched healthy controls. Secondary : 1) Characterize genetic predispositions of central sensitization in patients with FS compared to matched healthy controls, including confirmation of known genetic markers and potential identification of new genetic variants involved, 2) Compare in the area of central sensitization the population of patients with FS and matched healthy controls, 3) Compare in the domain of temporal summation the population of patients with FS and matched healthy controls, 4) Describe in the clinical field the characteristics of the FS patient population, 5) Compare in the areas of quality of life, anxiety/depression and comorbidities, characteristics of the FS patient population and matched healthy controls, 6) Compare epigenetic biomarkers of the FS patient population with healthy matched controls, 7) Study of the role of the gut microbiota in patients with FS (bio banking) 8) Compare in the areas of pain, sound and light sensitivity the population of patients with FS and matched healthy controls.
Tracking Information
- NCT #
- NCT04624581
- Collaborators
- Service de pharmacologie et toxicologie cliniques, Hôpitaux Universitaire Genève, Rue Gabrielle Perret-Gentil 4, 1205 Genève, SUISSE
- Association des Fibromyalgiques d'Auvergne, 19 Place de la Résistance, 63800 Cournon d'Auvergne, FRANCE
- Investigators
- Principal Investigator: Gisèle Pickering University Hospital, Clermont-Ferrand